BRAF and hepatocellular carcinoma: In 2008, sorafenib, a multikinase inhibitor active against vascular endothelial growth factor receptor (VEGFR) 2 and 3, fms like tyrosine kinase (FLT)3, KIT, platelet-derived growth factor receptor (PDGFR)β, RAF, BRAF WT, and BRAF V600E, was the first approved agent for advanced HCC.